Many diseases have been considered untreatable because there are no known molecules that can interrupt the given underlying biomolecular pathways. Totus uses high-throughput cell-based assays and large-scale machine learning to screen the activity of billions of compounds across the entire human genome, yielding new covalent drugs that can irreversibly bind to disease-causing proteins and silence them.
News & Insights
In The Media
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules